Pancreatic Cancer: Are We Making Progress?
Sep 29, 2017
Andrew Lowy, MD
Pancreatic Cancer: Are We Making Progress?

Andrew M. Lowy, MD serves as Professor of Surgery, Chief of the Division of Surgical Oncology and Leader of the Gastrointestinal Cancer Unit at the Moores UCSD Cancer Center. Dr. Lowy ‘s clinical and research interests are in the area of pancreatic and gastrointestinal cancer. Since 2005, Dr. Lowy has served as the surgical liaison for the Pancreatic Cancer Committee of the Southwest Oncology Group. From 2007-2016 he served as co-chair for the National Cancer Institute’s Pancreatic Cancer Task Force, and was elected chair in 2016. Dr. Lowy also serves on the board of the National Pancreas Foundation and as chair elect of the scientific and medical advisory board for the Pancreatic Cancer Action network. Currently, Dr. Lowy serves as the surgical principal investigator of RTOG 0848, the largest pancreatic cancer adjuvant trial ever to be conducted in the U.S. He previously served on the editorial board of the Annals of Surgical Oncology as section editor for pancreatic tumors, and has served as section editor for translational research since 2015. Dr. Lowy’s laboratory co-developed the first genetically engineered mouse model of pancreatic cancer and currently focuses on the study of tyrosine kinase signaling, preclinical therapeutics and preclinical modeling in pancreatic cancer. His laboratory has been continuously funded by the NIH since 1999.